These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 1710743)

  • 1. Bezafibrate retard in patients with insulin-dependent diabetes: effect on serum lipoproteins, fibrinogen, and glycemic control.
    Durrington PN; Winocour PH; Bhatnagar D
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():S30-4. PubMed ID: 1710743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia.
    Mackness MI; Bhatnagar D; Durrington PN; Prais H; Haynes B; Morgan J; Borthwick L
    Eur J Clin Nutr; 1994 Dec; 48(12):859-65. PubMed ID: 7889894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bezafibrate retard in type II diabetic patients: effects on hemostasis and glucose homeostasis.
    Mikhailidis DP; Mathur S; Barradas MA; Dandona P
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():platelet inhib/pd/ad/ae. PubMed ID: 1710742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria.
    Hollenbeck CB; Johnston P; Varasteh BB; Chen YD; Reaven GM
    Diabete Metab; 1991; 17(5):483-9. PubMed ID: 1752350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.
    Mathur S; Barradas MA; Mikhailidis DP; Dandona P
    Diabetes Res; 1990 Jul; 14(3):133-8. PubMed ID: 2132185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.
    Taniguchi A; Fukushima M; Sakai M; Tokuyama K; Nagata I; Fukunaga A; Kishimoto H; Doi K; Yamashita Y; Matsuura T; Kitatani N; Okumura T; Nagasaka S; Nakaishi S; Nakai Y
    Metabolism; 2001 Apr; 50(4):477-80. PubMed ID: 11288046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus.
    Winocour PH; Durrington PN; Bhatnagar D; Ishola M; Arrol S; Lalor BC; Anderson DC
    Diabet Med; 1990; 7(8):736-43. PubMed ID: 2147637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of short-term modest weight loss on fasting and post-prandial lipoprotein sub-fractions in type 2 diabetes mellitus patients.
    Ybarra J; James RW; Makoundou V; Bioletto S; Golay A
    Diabetes Metab; 2001 Dec; 27(6):701-8. PubMed ID: 11852380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemic type 2 (non-insulin-dependent) diabetic patients.
    Niort G; Cassader M; Gambino R; Pagano G
    Diabete Metab; 1992; 18(3):221-8. PubMed ID: 1397477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients.
    Waysbort J; Schwartz S; Brunner D
    Arzneimittelforschung; 1994 Nov; 44(11):1217-22. PubMed ID: 7893284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of bezafibrate on metabolic profiles in non-insulin-dependent diabetes mellitus.
    Alberti KG; Jones IR; Laker MF; Swai AB; Taylor R
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():S21-4; discussion S24-5. PubMed ID: 1710741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bezafibrate affects lipid, lipo- and apolipoprotein pattern in non-insulin-dependent diabetic patients.
    Niort G; Gambino R; Cassader M; Pagano G
    Horm Metab Res; 1993 Jul; 25(7):372-4. PubMed ID: 8406323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis.
    Pelegrí A; Romero R; Sentí M; Nogués X; Pedro-Botet J; Rubiés-Prat J
    Nephrol Dial Transplant; 1992; 7(7):623-6. PubMed ID: 1323073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes.
    Riccardi G; Genovese S; Saldalamacchia G; Patti L; Marotta G; Postiglione A; Rivellese A; Capaldo B; Mancini M
    Atherosclerosis; 1989 Feb; 75(2-3):175-81. PubMed ID: 2653325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
    Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U
    Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.
    Jonkers IJ; Mohrschladt MF; Westendorp RG; van der Laarse A; Smelt AH
    Am J Med; 2002 Mar; 112(4):275-80. PubMed ID: 11893366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum lipids, lipoproteins and macrovascular disease in non-insulin-dependent diabetics: a possible new approach to prevention.
    Seviour PW; Teal TK; Richmond W; Elkeles RS
    Diabet Med; 1988 Mar; 5(2):166-71. PubMed ID: 2964984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A therapeutic trial of bezafibrate on patients with hyperlipidemia with or without diabetes mellitus.
    Ho LT; Chiang HL; Tsai H; Chou TY; Kwok CF
    Proc Natl Sci Counc Repub China B; 1984 Jul; 8(3):240-5. PubMed ID: 6571590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.